The Columbia University Diabetes Research Center promotes diabetes research at the largest academic medical center in the largest U.S. metropolitan area. The DRC fosters integration with existing institutional centers of excellence in obesity, atherosclerosis, neurobiology, and cardiovascular biology. Its scientific themes are: (i) Integrated physiology of insulin action and resistance; (ii) Diabetes, dyslipidemia, and heart disease; (iii) Pancreas development, beta cell function, and cellular replacement therapies; (iv) Genetics and immunology of Type 1 Diabetes; (v) Global health, health disparities, and underserved urban populations. The Biomedical Research Base is comprised of 78 NIH-funded investigators at Columbia, and 4 associate members at sister institutions in New York City. Total research funding exceeds $ 81M in annual direct costs, including 91 investigator-initiated NIH grants directly related to diabetes totaling nearly $56M in annual direct costs. Of these, NIDDK funds 64 projects totaling $18M in annual direct costs. The DRC supports four technical Core Facilities: Translational Biomarker Analytical Core (TBAC); Advanced Tissue Pathology Imaging Core (ATPIC); Mouse Metabolic Function & Phenotyping Core (MMFPC); Cytometry & Cell Sorting Core (CCSC). These facilities have been used to capacity by 66 investigators funded by 102 grants and have supported the award of 45 new grants during the current cycle. Additionally, the DRC provides $250K annually for investigators through a Pilot & Feasibility Grant Program (PF). During the current cycle, this program supported 13 awardees selected from 90 Letters of Inquiry and 51 complete applications. The 11 recipients of completed PF awards have applied for 12 new grants and obtained 7, 6 of which are funded by NIH, totaling ~$ 2.8M in annual direct costs. 11 of 13 funded investigators remain active in diabetes research. The DRC supports a successful Enrichment Program to increase awareness of diabetes research